Published in J Biol Chem on December 06, 2011
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
Exploiting innate immune cell activation of a copper-dependent antimicrobial agent during infection. Chem Biol (2014) 1.58
Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med (2016) 1.48
Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease. Mol Neurodegener (2012) 0.97
Engineering enhanced protein disaggregases for neurodegenerative disease. Prion (2015) 0.96
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One (2013) 0.93
Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease. Front Aging Neurosci (2014) 0.84
Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol (2012) 0.84
The potential for transition metal-mediated neurodegeneration in amyotrophic lateral sclerosis. Front Aging Neurosci (2014) 0.84
Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity. Proc Natl Acad Sci U S A (2014) 0.84
Small Molecules Detected by Second-Harmonic Generation Modulate the Conformation of Monomeric α-Synuclein and Reduce Its Aggregation in Cells. J Biol Chem (2015) 0.82
RNA-Binding Proteins in Amyotrophic Lateral Sclerosis and Neurodegeneration. Neurol Res Int (2012) 0.81
Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease. Drug Discov Today Technol (2013) 0.80
Isolating potentiated Hsp104 variants using yeast proteinopathy models. J Vis Exp (2014) 0.79
Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases. Chem Cent J (2015) 0.77
Ubiquitin-dependent proteolysis in yeast cells expressing neurotoxic proteins. Front Mol Neurosci (2015) 0.77
Metal chaperones: a holistic approach to the treatment of Alzheimer's disease. Front Psychiatry (2012) 0.77
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. Acta Neuropathol Commun (2016) 0.77
Efforts to make and apply humanized yeast. Brief Funct Genomics (2015) 0.77
Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons. PLoS One (2015) 0.76
From the baker to the bedside: yeast models of Parkinson's disease. Microb Cell (2015) 0.75
Clioquinol synergistically augments rescue by zinc supplementation in a mouse model of acrodermatitis enteropathica. PLoS One (2013) 0.75
Scalable electrophysiology in intact small animals with nanoscale suspended electrode arrays. Nat Nanotechnol (2017) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science (2008) 14.09
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature (2010) 5.26
Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A (2004) 5.10
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet (2006) 4.01
Metalloproteins and metal sensing. Nature (2009) 3.97
Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A (2000) 3.82
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Metal ions in biological catalysis: from enzyme databases to general principles. J Biol Inorg Chem (2008) 2.87
TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol (2010) 2.81
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci (2010) 2.29
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet (2008) 2.03
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell (2010) 1.89
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev (2008) 1.81
Approaching a complete repository of sequence-verified protein-encoding clones for Saccharomyces cerevisiae. Genome Res (2007) 1.75
Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One (2010) 1.71
The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol (2010) 1.66
Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci (1996) 1.62
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol (2008) 1.56
Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet (2010) 1.56
Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci (2010) 1.46
TDP-43 in aging and Alzheimer's disease - a review. Int J Clin Exp Pathol (2011) 1.46
Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci (2010) 1.41
Metals and Alzheimer's disease. J Alzheimers Dis (2006) 1.39
Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 1.34
Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev (2004) 1.28
Yeast, a model organism for iron and copper metabolism studies. Biometals (2003) 1.22
Mechanisms of copper ion mediated Huntington's disease progression. PLoS One (2007) 1.08
The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J Biol Chem (2008) 1.01
Iron: a pathological mediator of Alzheimer disease? Dev Neurosci (2002) 0.98
Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci (2011) 0.95
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm (Vienna) (2004) 0.94
The metal chelating and chaperoning effects of clioquinol: insights from yeast studies. J Alzheimers Dis (2010) 0.90
Hsp90 as a capacitor of phenotypic variation. Nature (2002) 8.90
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell (2007) 8.84
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell (2011) 6.56
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell (2009) 6.20
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (2005) 5.04
Increase in activity during calorie restriction requires Sirt1. Science (2005) 4.90
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
A neuronal isoform of the aplysia CPEB has prion-like properties. Cell (2003) 4.16
Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science (2004) 4.01
Prions as adaptive conduits of memory and inheritance. Nat Rev Genet (2005) 3.97
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell (2012) 3.44
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
A suite of Gateway cloning vectors for high-throughput genetic analysis in Saccharomyces cerevisiae. Yeast (2007) 3.30
Cryptic variation in morphological evolution: HSP90 as a capacitor for loss of eyes in cavefish. Science (2013) 3.15
Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet (2009) 3.06
Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science (2002) 3.05
HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell (2012) 2.94
α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol (2010) 2.93
Prions are a common mechanism for phenotypic inheritance in wild yeasts. Nature (2012) 2.89
Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science (2013) 2.79
Hsp90 and environmental stress transform the adaptive value of natural genetic variation. Science (2010) 2.68
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
A natively unfolded yeast prion monomer adopts an ensemble of collapsed and rapidly fluctuating structures. Proc Natl Acad Sci U S A (2007) 2.62
Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science (2013) 2.61
Prion switching in response to environmental stress. PLoS Biol (2008) 2.61
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
Prion recognition elements govern nucleation, strain specificity and species barriers. Nature (2007) 2.57
Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci (2005) 2.50
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Prions as protein-based genetic elements. Annu Rev Microbiol (2002) 2.21
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell (2006) 2.14
Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc Natl Acad Sci U S A (2008) 2.09
Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell (2006) 2.09
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Under cover: causes, effects and implications of Hsp90-mediated genetic capacitance. Bioessays (2004) 2.02
Retracted SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci (2012) 2.00
Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science (2002) 1.99
The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc Natl Acad Sci U S A (2007) 1.99
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci (2006) 1.98
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
Prion protein is expressed on long-term repopulating hematopoietic stem cells and is important for their self-renewal. Proc Natl Acad Sci U S A (2006) 1.92
Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin Ther Targets (2009) 1.91
Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol (2013) 1.88
Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. Annu Rev Genet (2010) 1.88
Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci U S A (2008) 1.88
HSP90 affects the expression of genetic variation and developmental stability in quantitative traits. Proc Natl Acad Sci U S A (2008) 1.87
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
Widespread regulation of translation by elongation pausing in heat shock. Mol Cell (2013) 1.85
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Epigenetics in the extreme: prions and the inheritance of environmentally acquired traits. Science (2010) 1.84
Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J (2008) 1.82
Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev (2008) 1.81
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
Asymmetric deceleration of ClpB or Hsp104 ATPase activity unleashes protein-remodeling activity. Nat Struct Mol Biol (2007) 1.77
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet (2006) 1.77
Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc Natl Acad Sci U S A (2006) 1.76
Polyamine pathway contributes to the pathogenesis of Parkinson disease. Proc Natl Acad Sci U S A (2010) 1.73
Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol (2010) 1.63
Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A (2004) 1.62
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
An intrinsically disordered yeast prion arrests the cell cycle by sequestering a spindle pole body component. J Cell Biol (2012) 1.60
Blessings in disguise: biological benefits of prion-like mechanisms. Trends Cell Biol (2013) 1.56
Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell (2007) 1.56
The prion protein knockout mouse: a phenotype under challenge. Prion (2007) 1.51
Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp (2008) 1.50
Opposing effects of glutamine and asparagine govern prion formation by intrinsically disordered proteins. Mol Cell (2011) 1.49
Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron (2009) 1.49
MEC-2 is recruited to the putative mechanosensory complex in C. elegans touch receptor neurons through its stomatin-like domain. Curr Biol (2004) 1.47
Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci (2010) 1.46
Mechanisms of protein-folding diseases at a glance. Dis Model Mech (2014) 1.45
HSP90-buffered genetic variation is common in Arabidopsis thaliana. Proc Natl Acad Sci U S A (2008) 1.45
Prion induction involves an ancient system for the sequestration of aggregated proteins and heritable changes in prion fragmentation. Proc Natl Acad Sci U S A (2010) 1.43
A heritable switch in carbon source utilization driven by an unusual yeast prion. Genes Dev (2009) 1.43
Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegans. Hum Mol Genet (2004) 1.42
Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition. Nat Methods (2013) 1.41
Prion protein gene polymorphisms in Saccharomyces cerevisiae. Mol Microbiol (2003) 1.41
Phenotypic diversity and altered environmental plasticity in Arabidopsis thaliana with reduced Hsp90 levels. PLoS One (2007) 1.39